respiratori
multiplex
platform
assay
significantli
improv
treatment
respiratori
infect
reduc
associ
complic
four
major
fdaapprov
respiratori
multiplex
assay
luminex
nxtag
respiratori
pathogen
panel
rpp
nanospher
verigen
respiratori
panel
rp
flex
biofir
film
array
respiratori
panel
rp
esensor
respiratori
viral
panel
rvp
treatment
clinic
manag
respiratori
tract
infect
rti
depend
etiolog
agent
abil
rapidli
character
respiratori
pathogen
extrem
import
multiplex
method
particularli
valuabl
case
rti
allow
clinician
simultan
test
wide
rang
possibl
pathogen
oppos
reli
numer
individu
test
correct
diagnosi
rti
also
critic
antibiot
stewardship
sinc
roughli
antibiot
prescrib
unnecessari
unneed
prescript
respiratori
infect
anoth
challeng
diagnos
rti
across
geograph
region
respiratori
diseas
preval
may
season
regionspecif
broad
spectrum
assay
screen
varieti
target
would
identifi
chang
season
trend
significantli
impact
region
clinic
decis
throughout
year
rsv
respiratori
syncyti
viru
infect
exampl
season
affect
differ
part
unit
state
differ
time
year
outbreak
vari
within
region
commun
multiplex
method
also
help
resolv
genotyp
variat
recogn
genotyp
differ
help
diagnosi
determin
cours
clinic
treatment
instanc
adamantineresist
strain
circul
global
past
decad
oseltamivirresist
season
circul
global
sinc
influenza
season
predomin
strain
compar
year
earlier
preval
trend
call
attent
need
identifi
also
character
respiratori
pathogen
possibl
circumv
ineffect
treatment
benefit
multiplex
assay
result
increas
number
hospit
clinic
laboratori
adopt
method
strictli
clinic
use
multiplex
technolog
help
aid
clinic
decis
simultan
screen
varieti
respiratori
pathogen
often
detect
specif
genet
differ
increas
valu
method
diagnost
purpos
exampl
children
older
adult
influenza
rsv
primari
medic
burden
requir
distinct
treatment
thu
resolv
caus
infect
critic
surveil
limit
studi
shown
epidemiolog
use
technolog
control
prevent
howev
use
respiratori
multiplex
assay
tremend
benefit
public
health
exampl
despit
includ
firstgener
luminex
xtag
rvp
releas
result
could
still
use
ruleout
method
strain
use
luminex
xtag
rvp
allow
rapid
diagnosi
better
surveil
outbreak
similarli
outbreak
esensor
rvp
filmarray
rp
use
reliabl
diagnost
test
surveil
algorithm
distinguish
rhinoviru
mitig
spread
diseas
multiplex
diagnost
assay
potenti
revolution
diseas
surveil
howev
technolog
great
impact
control
prevent
effort
compar
healthcar
util
surveil
need
fundament
differ
clinic
diagnost
prioriti
wherea
diagnost
assay
use
identifi
diseas
etiolog
appropri
treatment
infect
individu
diseas
surveil
conduct
popul
level
identifi
trend
diseas
burden
despit
substanti
benefit
eg
high
effici
rapid
turnaround
time
high
throughput
screen
multitud
target
multiplex
assay
enhanc
surveil
effort
comprehens
review
assess
multiplex
assay
meet
surveil
need
whether
futur
studi
focu
specif
laboratori
need
perform
surveil
outbreak
test
review
primari
barrier
use
multiplex
assay
rti
surveil
focus
limit
current
respiratori
multiplex
assay
surveil
abl
highlight
altern
method
evalu
perform
new
multiplex
assay
better
meet
need
program
conduct
surveil
luminex
corpor
austin
texa
unveil
xtag
high
complex
high
throughput
beadbas
qualit
pcr
assay
capabl
detect
varieti
respiratori
pathogen
xtag
assay
first
fdaapprov
broad
respiratori
panel
extens
use
clinic
public
health
laboratori
phl
util
bead
hybrid
fluid
array
current
version
panel
luminex
nxtag
rpp
screen
total
target
nasopharyng
specimen
np
rsv
type
b
influenza
variant
influenza
influenza
b
parainfluenza
human
metapneumoviru
hmpv
adenoviru
rhinovrusenteroviru
coronaviru
type
human
bocaviru
bacteri
target
c
pneumonia
pneumonia
result
sampl
obtain
singl
work
day
h
postextract
verigen
system
manufactur
luminex
moder
complex
customiz
throughput
assay
detect
varieti
pathogen
found
major
fdaapprov
respiratori
multiplex
panel
bordetella
spp
group
verigen
platform
consist
reader
separ
process
unit
capabl
sampletoresult
h
minim
handson
time
fulli
autom
recent
panel
offer
verigen
system
respiratori
pathogen
flex
rp
flex
receiv
fda
approv
panel
screen
virus
bacteria
highlight
bordetella
spp
bacteri
group
rp
flex
first
multiplex
respiratori
test
allow
custom
user
report
prefer
allow
pay
need
option
five
report
block
may
releas
user
block
adenoviru
hmpv
block
influenza
influenza
b
block
parainfluenza
rhinoviru
block
rsv
b
block
b
pertussi
b
holmesii
b
parapertussisbbronchiseptica
onboard
pcr
multiplex
perform
target
result
preselect
paid
report
endem
circul
virus
may
target
specif
popul
budget
target
interest
exampl
block
block
may
great
interest
laboratori
serv
senior
pediatr
popul
outbreak
rsv
adenoviru
common
subpopul
addit
flu
season
block
would
give
great
profil
circul
influenza
virus
diagnost
laboratori
surveil
populationbas
trend
data
highli
valu
therefor
flex
option
would
like
bypass
favor
fix
report
target
genmark
diagnost
inc
carlsbad
california
receiv
fda
approv
esensor
rvp
high
complex
highthroughput
assay
assay
run
genmark
instrument
modular
system
integr
one
three
analyz
process
eight
sampl
screen
viral
respiratori
pathogen
initi
workflow
begin
min
prep
time
follow
h
place
system
respiratori
viral
panel
contain
sever
influenza
target
rsv
subtyp
parainfluenza
type
hmpv
addit
panel
report
rhinoviru
instead
combin
rhinovirusenteroviru
result
howev
crossreact
enteroviru
report
panel
also
multiplex
panel
specif
detect
adenoviru
type
c
filmarray
rp
fdaapprov
lowthroughput
moderatelow
complex
multiplex
nest
pcr
assay
autom
extract
result
assay
abl
identifi
character
viral
well
three
bacteri
pathogen
manufactur
biofir
diagnost
salt
lake
citi
utah
viral
target
includ
adenoviru
coronaviru
hmpv
rhinovrusenteroviru
influenza
influenza
subtyp
influenza
b
parainfluenza
rsv
three
bacteri
target
includ
b
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
major
benefit
filmarray
rp
minim
handson
oper
time
minsampl
system
includ
onboard
autom
nucleic
acid
extract
directli
np
sampl
timetoresult
h
drawback
filmarray
rp
system
one
sampl
process
time
thu
singl
workday
total
sampl
may
process
filmarray
system
receiv
fda
clearanc
earli
updat
model
could
includ
eight
modular
unit
sequenti
link
one
pc
allow
higher
throughput
earli
biofir
diagnost
subsidiari
biomerieux
receiv
fda
clearanc
expand
instrument
system
filmarray
torch
newer
platform
compris
scalabl
modul
may
includ
system
capabl
screen
sampl
per
workday
newer
platform
follow
technolog
allow
process
rp
assay
primari
differ
preanalyt
test
requir
diseas
surveil
clinic
diagnosi
begin
specimen
collect
healthcar
facil
collect
specimen
individu
exhibit
rti
symptom
likelihood
identifi
sourc
infect
high
select
specimen
collect
clinic
lab
minim
unnecessari
test
turn
reduc
cost
use
medic
servic
laboratori
perform
surveillancebas
test
specimen
collect
symptomat
asymptomat
individu
compar
test
result
symptomat
healthi
individu
provid
evid
base
epidemiolog
associ
critic
activ
surveil
studi
report
mani
viral
respiratori
infect
may
go
unreport
due
lack
symptom
thu
monitor
asymptomat
individu
potenti
mitig
spread
infect
detect
asymptomat
carrier
respiratori
diseas
anoth
differ
clinic
surveil
test
occur
specimen
process
four
current
major
fdaapprov
multiplex
assay
filmarray
rp
nanospher
rp
flex
luminex
nxtag
rvp
genmark
esensor
rvp
receiv
fda
approv
test
np
despit
sever
proofofprincip
studi
shown
compar
diagnost
sen
spe
use
sampl
type
eg
sputum
bronchoalveolar
lavag
fluid
bronchial
wash
anterior
nare
swab
throat
swab
tracheal
aspir
process
specimen
type
collect
method
requir
addit
independ
studi
test
laboratori
especi
result
use
make
clinic
decis
independ
studi
includ
analyt
valid
studi
labdevelop
test
ldt
establish
compar
precis
accuraci
refer
rang
report
rang
laboratori
also
requir
assess
addit
assay
perform
characterist
eg
analyt
specif
analyt
sensit
linear
surveil
test
similar
independ
studi
requir
especi
result
report
healthcar
agenc
clinic
purpos
howev
surveil
test
use
establish
diseas
trend
reveal
etiolog
varieti
sampl
type
often
collect
process
sinc
microbi
load
unknown
may
higher
one
type
anoth
report
result
surveil
lab
also
requir
perform
addit
independ
valid
studi
report
result
research
use
investig
use
requir
addit
valid
sampl
type
like
limit
adopt
multiplex
assay
surveil
purpos
final
differ
number
sampl
typic
process
clinic
diagnost
surveil
work
effect
clinic
care
depend
rapid
turnaround
time
clinic
lab
like
process
sampl
individu
smaller
batch
identifi
sourc
outbreak
rapid
result
critic
control
prevent
also
requir
small
batch
test
howev
routin
surveil
whose
aim
trend
popul
data
sampl
test
larg
batch
minim
cost
howev
larg
batch
test
often
possibl
multiplex
assay
due
inher
design
manufactur
instanc
filmarray
rp
nanospher
rp
flex
process
one
sampl
time
luminex
nxtag
rpp
esensor
rvp
process
multipl
sampl
one
time
note
need
filmarray
rp
nanospher
rp
flex
allow
modular
expans
test
one
sampl
time
even
limit
number
sampl
process
one
time
thu
need
surveil
lab
perform
larg
batch
test
met
like
slow
adopt
respiratori
multiplex
assay
surveil
lab
also
differ
consid
whether
assay
use
either
clinic
diagnosi
surveil
postanalyt
phase
test
origin
intend
use
major
fdaapprov
respiratori
multiplex
assay
provid
rapid
result
aid
clinic
manag
result
sinc
commerci
releas
assay
studi
mostli
report
postanalyt
use
respiratori
multiplex
result
clinic
set
howev
postanalyt
interpret
result
vari
depend
test
result
use
exampl
healthcar
set
result
multiplex
test
use
help
manag
patient
care
howev
surveil
test
result
use
trend
popul
data
identifi
caus
agent
outbreak
confirm
case
slight
differ
signific
must
resolv
comparison
sen
spe
potenti
hold
much
valu
clinic
diagnos
help
understand
critic
attribut
multiplex
assay
surveil
requir
broader
epidemiolog
diagnost
approach
diagnost
measur
captur
strength
direct
associ
help
epidemiologist
strateg
control
prevent
effort
would
use
measur
dor
roc
curv
youden
index
j
may
serv
good
altern
sen
spe
fill
need
dor
interpret
ratio
odd
posit
test
presenc
diseas
odd
posit
test
absenc
diseas
higher
dor
better
discriminatori
power
test
dor
calcul
likelihood
ratio
likelihood
ratio
equival
dor
differenti
popul
diseas
without
diseas
base
likelihood
posit
test
result
equival
calcul
sen
spe
specif
assay
measur
dor
show
overal
strength
epidemiolog
import
associ
test
result
diseas
instanc
larger
dor
would
describ
strong
associ
convers
low
dor
would
describ
weaker
associ
higher
dor
translat
better
discriminatori
test
perform
identifi
patient
diseas
report
sen
spe
k
fda
approv
summari
report
major
fdaapprov
respiratori
multiplex
assay
summar
tabl
along
dor
assay
target
avail
per
assay
dor
fdaapprov
multiplex
respiratori
assay
high
dictat
assay
good
discriminatori
power
strength
associ
assay
vari
depend
target
ie
pathogen
interest
result
assay
best
depend
target
studi
esensor
rvp
show
greater
diagnost
perform
multiplex
assay
ie
filmarray
rp
luminex
nxtag
rpp
confirm
outbreak
case
adenoviru
specif
type
bc
e
common
unit
state
recent
contrast
filmarray
rp
perform
better
compar
assay
influenza
type
b
nanospher
rp
flex
perform
better
compar
assay
bordetella
bacteri
target
ie
b
pertussi
b
parapertussisb
bronchiseptica
b
holmesii
summari
best
assay
among
target
overlap
across
assay
filmarray
rp
howev
target
overlap
mani
assay
varieti
respiratori
pathogen
target
panel
thu
best
perform
assay
need
evalu
per
target
basi
roc
curv
provid
altern
approach
evalu
diagnost
perform
provid
epidemiolog
insight
guidanc
differenti
use
respiratori
multiplex
assay
roc
curv
simpl
visual
allow
comparison
classifi
ie
test
plot
true
posit
rate
trp
sen
fals
posit
rate
fpr
rti
fp
repres
signific
burden
healthcar
system
especi
infect
vulner
subpopul
individu
coinfect
exacerb
alreadi
exist
condit
surveil
fp
repres
case
misalloc
resourc
effort
requir
treat
nonexist
condit
hope
mitig
spread
diseas
subpopul
compar
routin
clinic
care
routin
surveil
fp
much
greater
burden
healthcar
industri
especi
test
either
expens
followup
invas
expens
within
roc
space
point
fpr
tpr
lefthand
side
denot
classifi
exhibit
better
perform
random
chanc
figur
better
perform
classifi
alway
prefer
discriminatori
line
separ
liber
conserv
classifi
point
liber
space
repres
classifi
like
identifi
tp
despit
weak
signal
expens
high
fpr
convers
point
conserv
space
identifi
tp
presenc
strong
signal
expens
low
fpr
outbreak
novel
respiratori
variant
eg
influenza
coronaviru
high
fpr
accept
especi
assur
identifi
tp
appropri
control
prevent
could
mitig
spread
infect
addit
milder
form
rti
go
unreport
everi
respiratori
infect
detect
mani
reason
true
preval
incid
difficult
estim
high
fpr
respiratori
multiplex
test
could
potenti
minim
error
know
true
preval
estim
includ
fals
posit
total
number
posit
observ
may
ideal
correct
true
preval
estim
high
fpr
assay
could
help
approach
true
burden
diseas
final
roc
space
plot
analysi
clinic
decis
benefit
use
conserv
diagnost
test
howev
routin
surveil
liber
diagnost
test
would
effect
use
roc
space
provid
valuabl
method
compar
major
fdaapprov
respiratori
multiplex
assay
either
clinic
diagnost
surveil
use
upon
closer
inspect
roc
space
plot
figur
import
similar
differ
aris
filmarray
rp
nanospher
rp
flex
luminex
nxtag
rpp
esensor
rvp
assay
better
perform
random
chanc
slight
major
target
call
lie
conserv
side
discrimin
suggest
consid
assay
whole
perform
fals
posit
report
call
correctli
identifi
posit
infect
everi
assay
call
throughout
roc
space
suggest
despit
overal
liber
conserv
classif
assay
assay
could
still
use
either
patient
care
surveil
roc
space
plot
also
reveal
conserv
multiplex
assay
luminex
nxtag
rpp
suggest
assay
would
benefici
assay
use
clinic
diagnost
purpos
liber
test
esensor
rvp
would
serv
well
perform
surveil
work
roc
space
plot
also
make
per
target
assay
specif
recommend
filmarray
rp
lowest
fpr
across
target
except
liber
call
rhinovirusenteroviru
rsv
conserv
call
adenoviru
infect
thu
outbreak
rhinovirusenteroviru
rsv
filmarray
rp
would
perform
much
better
assay
nanospher
rp
flex
also
low
fpr
unlik
filmarray
rp
hardli
make
liber
call
except
rsv
b
suggest
greater
clinic
applic
other
highli
relev
clinic
public
health
target
eg
influenza
influenza
b
filmarray
rp
nearli
perfect
detect
rel
fals
posit
correctli
identifi
posit
infect
pandem
potenti
target
coronavirus
filmarray
rp
excel
diagnost
test
higher
sen
lower
fpr
compar
assay
sole
except
detect
slightli
better
luminex
nxtag
rpp
two
assay
screen
bordetella
spp
filmarray
rp
nanospher
rp
flex
among
two
assay
nanospher
rp
flex
near
perfect
assay
correctli
call
posit
bordetella
spp
infect
worst
perform
target
across
assay
conserv
call
parainfluenza
luminex
nxtag
rpp
parainfluenza
luminex
nxtag
rpp
b
pertussi
filmarray
rp
use
roc
plot
assess
graphic
diagnost
valu
respiratori
multiplex
assay
add
tremend
valu
target
could
evalu
independ
target
comparison
target
across
multiplex
assay
anoth
use
epidemiolog
measur
often
present
conjunct
roc
curv
youden
index
j
j
statist
summari
measur
similar
dor
incorpor
sen
spe
j
interpret
diagnost
test
maximum
effect
repres
optim
cutoff
threshold
maximum
differ
tpr
fpr
exist
essenti
j
point
sen
roc
space
defin
diagnost
test
abl
correctli
identifi
posit
fewest
fals
posit
j
valu
j
graphic
repres
farthest
point
roc
space
away
random
perform
j
express
j
depend
diseas
preval
requir
dichotom
test
result
may
alway
applic
depend
target
instanc
character
influenza
strain
filmarray
rp
give
one
three
result
detect
detect
equivoc
detect
rsv
panel
either
detect
detect
similarli
luminex
xtag
rvp
provid
equivoc
result
target
evalu
respiratori
multiplex
assay
j
provid
simpl
measur
diagnost
effect
upon
calcul
j
respiratori
multiplex
assay
heat
map
figur
present
allow
visual
comparison
diagnost
perform
could
use
either
patient
care
surveil
lighter
color
closer
j
interpret
target
detect
much
better
respect
assay
grey
box
indic
target
screen
respect
assay
heat
map
particularli
use
identifi
assay
best
suit
confirm
coinfect
respond
rapidli
clinic
diagnosi
surveil
exampl
rsv
rhinoviru
coinfect
associ
sever
pediatr
diseas
first
better
perform
assay
detect
rhinoviru
identifi
per
heat
map
either
luminex
nxtag
rpp
filmarray
rp
next
consider
need
confirm
either
rsv
rsv
rsv
b
done
filmarray
rp
confirm
rsv
luminex
nxtag
rpp
confirm
either
rsv
rsv
b
knowledg
rsv
implic
sever
complic
rsv
b
luminex
nxtag
rpp
would
best
suitabl
assay
confirm
coinfect
rsv
rhinoviru
surveil
method
identifi
best
perform
assay
coinfect
use
similar
heat
map
could
appli
reduc
probabl
larg
outbreak
collect
use
dor
roc
space
plot
j
allow
uniqu
method
evalu
fda
respiratori
multiplex
assay
surveil
use
measur
provid
uniqu
inform
add
surveil
strategi
aid
diagnosi
mitig
spread
diseas
dor
allow
control
prevent
program
identifi
strength
direct
associ
test
result
presenc
absenc
diseas
roc
space
plot
allow
differenti
better
wors
perform
assay
per
target
basi
j
supplement
measur
use
minim
number
fals
posit
fals
neg
overal
evalu
base
measur
fdaapprov
multiplex
respiratori
assay
biofir
filmarray
rp
recommend
platform
surveil
use
respiratori
pathogen
howev
evalu
surveil
specif
target
bordetella
spp
rsv
recommend
platform
use
nanospher
verigen
rp
flex
surveil
detect
untyp
influenza
biofir
filmarray
rp
recommend
confirm
adenoviru
infect
genmark
esensor
rvp
recommend
base
roc
space
plot
luminex
nxtag
rvp
suitabl
clinic
diagnos
major
target
recommend
base
current
formul
report
fda
summari
report
assay
would
chang
upon
releas
newer
version
panel
dor
correl
sen
spe
ie
high
sen
low
spe
correspond
high
dor
low
dor
respect
dor
provid
support
inform
serv
practic
need
sinc
sen
spe
could
use
direct
proxi
best
addit
measur
would
help
epidemiologist
understand
perform
multiplex
assay
sinc
odd
ratio
terminolog
well
known
within
field
howev
correl
dor
sen
spe
differ
enough
dor
must
treat
essenti
measur
reveal
uniqu
interpret
use
multiplex
assay
compar
dor
sen
correl
coeffici
fdaapprov
multiplex
assay
rang
suggest
poor
correl
despit
posit
associ
overal
figur
similarli
compar
dor
spe
correl
coeffici
assay
rang
also
suggest
poor
posit
correl
figur
b
standard
posit
correl
exist
near
consid
highli
correl
despit
overal
low
posit
correl
assay
interpret
assay
perform
target
differ
instanc
high
dor
highli
correl
high
sen
convers
low
dor
low
sen
trend
observ
spe
howev
high
correl
target
specif
assay
low
suggest
sen
spe
use
epidemiolog
measur
assess
respiratori
multiplex
assay
perform
overal
dor
separ
uniqu
measur
add
signific
epidemiolog
valu
assess
use
multiplex
assay
despit
tremend
potenti
benefit
respiratori
multiplex
technolog
surveil
assay
without
limit
one
import
aspect
design
pcrbase
assay
primer
select
fdaapprov
multiplex
respiratori
technolog
present
contain
primer
pool
probe
correspond
common
respiratori
target
optim
primer
yield
reliabl
qualit
result
target
individu
panel
howev
univers
challeng
manufactur
select
appropri
genom
target
sequenc
optim
hybrid
therebi
minim
unwant
nonspecif
interact
could
lead
diagnost
error
ie
fp
fn
two
target
challeng
manufactur
adenoviru
rhinovirusenteroviru
earli
assay
releas
luminex
xtag
rvp
biofir
filmarray
rp
report
poor
adenoviru
detect
result
reduc
sensit
present
clinic
contriv
sampl
current
version
filmarray
rp
xtag
rvp
includ
updat
primer
align
complet
code
sequenc
adenoviru
serotyp
updat
filmarray
rp
panel
shown
diagnost
improv
previou
version
esensor
rvp
multiplex
assay
capabl
detect
subgroup
c
surveil
assay
choic
depend
surveil
popul
need
increas
dor
order
major
fdaapprov
respiratori
multiplex
panel
design
nanospher
rp
flex
filmarray
rp
luminex
nxtag
rpp
problemat
target
respiratori
multiplex
test
rhinovirus
enterovirus
due
genet
homolog
pathogen
lack
resolut
detect
either
luminex
nxtag
rvp
filmarray
rp
result
detect
simpli
report
either
rhinoviru
rhinovirusenteroviru
without
differenti
primer
similar
rhinovirus
enterovirus
increas
risk
crossamplif
interfer
multiplex
test
per
product
insert
nanospher
rp
flex
observ
crossreact
rhinovirusenteroviru
primer
human
polioviru
coxsackieviru
sampl
call
posit
rhinovirusenteroviru
laboratori
reflex
either
cultur
sequenc
resolv
identif
detect
followup
test
rhinovirusenteroviru
sampl
becom
import
concern
due
nationwid
outbreak
across
unit
state
symptom
includ
hallmark
cold
symptom
fever
runni
nose
muscl
ach
well
difficulti
breath
recent
studi
sinc
describ
associ
infect
acut
flaccid
myeliti
relat
acut
flaccid
paralysi
highlight
import
good
resolut
rhinoviru
enteroviru
respiratori
multiplex
assay
similar
primer
crossreact
issu
present
coronaviru
virus
filmarray
rp
assay
anoth
limit
respiratori
multiplex
assay
precis
quantif
infect
determin
assay
present
fdaapprov
qualit
test
unabl
determin
viral
bacteri
load
avail
may
help
surveil
identifi
appropri
case
definit
addit
cost
respiratori
multiplex
test
signific
limit
must
justifi
clinic
care
set
surveil
effort
use
respiratori
multiplex
assay
costlier
tradit
method
everi
program
justifi
use
platform
without
establish
patient
populationbas
outcom
howev
use
respiratori
multiplex
assay
lead
overal
cost
save
set
use
xtag
combin
serolog
cultur
result
cost
save
approxim
four
hospit
screen
pediatr
patient
xtag
also
improv
laboratori
effici
well
reduc
laboratori
cost
increas
workflow
similarli
implement
filmarray
rp
improv
treatment
stewardship
influenza
influenza
b
dramat
improv
patient
care
rel
cost
multiplex
respiratori
assay
previous
compar
show
increas
cost
order
filmarray
rp
esensor
rvp
xtag
nanospher
verigen
rp
flex
consid
econom
feasibl
fdaapprov
respiratori
multiplex
assay
market
laboratori
charg
preselect
target
result
remain
target
hidden
addit
cost
consid
includ
throughput
turnaround
time
overal
cost
benefit
analysi
necessari
everi
laboratori
program
consid
implement
respiratori
multiplex
test
current
landscap
respiratori
multiplex
test
includ
varieti
technolog
revolution
clinic
practic
howev
due
specif
barrier
technolog
could
impact
surveil
effort
even
despit
numer
studi
show
realworld
applic
full
adopt
method
routin
surveil
test
outbreak
respons
limit
larg
part
due
technolog
evalu
compar
cultur
serolog
fdaapprov
assay
present
report
provid
equival
sen
spe
measur
tradit
marker
diagnost
perform
howev
better
measur
diagnost
perform
dor
roc
space
plot
youden
index
make
assay
use
result
interpret
clearer
much
effect
surveil
use
measur
allow
comparison
pertarget
basi
provid
much
specif
use
technolog
surveil
allow
epidemiolog
strength
associ
direct
determin
addit
measur
restrict
multiplex
respiratori
platform
could
also
critic
use
class
multiplex
assay
panel
eg
enter
panel
blood
cultur
mening
next
year
see
evolut
respiratori
multiplex
technolog
rapid
effici
easier
use
easier
interpret
panel
capabl
screen
broader
rang
pathogen
challeng
bestow
laboratori
evalu
newer
technolog
meet
public
health
demand
respiratori
multiplex
assay
greatli
impact
patient
care
reduc
turnaround
time
increas
throughput
offer
greater
diagnost
valid
convent
method
sen
spe
highli
valu
determin
better
perform
assay
clinic
applic
howev
measur
limit
use
surveil
sinc
evalu
impact
multiplex
assay
populationbas
outcom
requir
measur
captur
epidemiolog
associ
express
perform
assay
populationbas
level
measur
express
broader
epidemiolog
impact
respiratori
multiplex
assay
would
use
mitig
diseas
transmiss
help
control
prevent
effort
identifi
better
perform
assay
popul
light
need
dor
roc
space
plot
youden
index
plausibl
measur
use
nontradit
evalu
measur
establish
strength
direct
associ
test
result
presenc
diseas
also
allow
communic
control
program
identifi
better
perform
assay
popul
would
greatli
aid
outbreak
respons
manufactur
evalu
measur
creat
opportun
reveal
panel
target
panel
perhap
reformul
recommend
surveil
use
implic
evalu
multiplex
assay
surveil
effort
instead
clinic
use
reach
beyond
respiratori
diseas
rti
use
case
studi
report
multiplex
assay
exist
screen
varieti
pathogen
antibioticresist
organ
kpcproduc
carbapenemresist
enterobacteriacea
cre
report
everi
state
decemb
healthcar
set
moral
rate
cre
infect
may
high
group
current
vergien
gramneg
blood
cultur
test
multiplex
molecular
assay
identifi
gramneg
bacilli
blood
cultur
also
varieti
resist
mechan
includ
kpc
oxa
imp
vim
also
commerci
avail
cepheid
xpert
carbar
multiplex
assay
identifi
differenti
carbapenemas
gene
famili
perform
evalu
assay
other
surveil
would
distinguish
better
perform
assay
weaker
test
greatli
aid
epidemiolog
strategi
curb
spread
antibiot
resist
help
lower
burden
diseas
within
five
year
multiplex
respiratori
assay
becom
rapid
comprehens
autom
nextgener
sequenc
ng
platform
assay
domin
diagnost
market
surveil
purpos
ng
technolog
power
highthroughput
tool
capabl
varieti
differ
healthcar
nonhealthcar
applic
introduct
ng
alreadi
began
shift
public
health
practic
diagnost
method
multiplex
ng
shown
confirm
viral
infect
detect
pcrbase
multiplex
assay
similarli
graf
et
al
show
reliabl
metagenom
specif
ngstype
analysi
compar
method
esensor
rvp
agreement
also
detect
addit
pathogen
surveil
ng
provid
detail
genom
inform
aid
identifi
resist
virul
sequenc
chang
time
one
biggest
challeng
appli
ng
toward
surveil
need
fda
regulatori
standard
method
ng
present
uniqu
regulatori
challeng
requir
evalu
perform
also
big
data
pipelin
use
determin
character
phylogenet
relationship
howev
benefit
ng
provid
detail
omic
inform
could
significantli
improv
surveil
greatli
outweigh
regulatori
big
data
challeng
advanc
multiplex
pcr
instrument
system
replac
tradit
method
detect
respiratori
pathogenswithin
past
decad
sever
multiplex
platform
luminex
nxtag
rpp
verigen
rp
flex
esensor
rvp
filmarray
rp
acquir
fda
approv
use
public
health
clinic
laboratori
fdaapprov
respiratori
multiplex
assay
success
demonstr
public
health
benefit
varieti
patient
populationsfrom
clinic
standpoint
respiratori
multiplex
assay
evalu
use
need
compar
sen
spefrom
surveil
perspect
respiratori
multiplex
assay
evalu
base
epidemiolog
relev
interpret
measur
dor
roc
space
plot
youden
indexdor
reveal
direct
strength
associ
test
result
presenc
absenc
diseaseroc
space
plot
youden
index
great
tool
compar
diagnost
assay
per
target
basi
aid
outbreak
responsecomparison
dor
sen
spe
show
low
posit
correl
suggest
dor
uniqu
measur
add
valuabl
inform
regard
perform
multiplex
assayslimit
use
multiplex
assay
includ
primer
select
costsurveil
measur
use
evalu
varieti
multiplex
assay
use
confirm
ruleout
diseas
antibioticresist
organ
